Radiotherapy of Head and Neck Cancer With SIB

Launched by WUERZBURG UNIVERSITY HOSPITAL · Feb 12, 2025

Keywords

ClinConnect Summary

This clinical trial, titled "Radiotherapy for Head and Neck Tumors with SIB," is investigating a treatment approach for patients with head and neck cancers. Specifically, it aims to understand how effective and safe a method called simultaneous integrated boost (SIB) is when used in combination with radiation and chemotherapy. The study will look at various important factors, such as how well the treatment controls the cancer, overall survival rates, and the side effects experienced by patients. Additionally, researchers will assess how this treatment impacts patients' quality of life during and after therapy.

To participate in the trial, individuals must be at least 18 years old and have been diagnosed with a malignant head and neck tumor. They should be receiving radiation or chemotherapy treatment at the University Hospital Würzburg. Participants will not only contribute to important research but will also help improve future treatments for others facing similar challenges. Throughout the study, researchers will carefully document the experiences of participants to ensure that the findings reflect real-world outcomes.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients aged 18 and older with histologically confirmed malignant head and neck tumors, undergoing definitive or adjuvant radio(chemo)therapy at the University Hospital Würzburg
• Exclusion Criteria:
• • missing informed consent
• • mental or physical disorders leading to inability to understand and/or fill the quationary
• • judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures